To understand the different effects of LAP2α on proliferation in progeria and WT cells, we analyzed the proliferation properties of mid-passage (p13–p17) dermal fibroblasts derived from HGPS patients and from healthy control individuals in relation to their progerin and LAP2α levels. The gene discussed is LMNA; the disease is progeroid syndrome.